US equities |
MU $1,088.00 ▲+0.00% META $721.31 ▲+0.00% GOOGL $350.50 ▲+0.00% NVDA $237.47 ▲+0.00% SNDK $1,692.42 ▲+0.00% INTC $113.12 ▲+0.00% JPM $329.58 ▲+0.00% AMD $645.86 ▲+0.00%
FinancialContent

Articles published by Xilio Therapeutics, Inc.

< Previous 1 2 Next >
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers ANIK XLO
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Announces Pricing of Underwritten Offering
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
News headline image
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Tickers XLO
< Previous 1 2 Next >